111 related articles for article (PubMed ID: 10740639)
21. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
Pradermdee P; Manusirivithaya S; Tangjitgamol S; Thavaramara T; Sukwattana P
J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140
[TBL] [Abstract][Full Text] [Related]
22. Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide.
Shih V; Wan HS; Chan A
Ann Pharmacother; 2009 Mar; 43(3):444-52. PubMed ID: 19193584
[TBL] [Abstract][Full Text] [Related]
23. A randomized trial to compare the efficacy and safety of antiemetic treatment with ondansetron and ondansetron zydis in patients with breast cancer treated with high-dose epirubicin.
Pectasides D; Dafni U; Aravantinos G; Timotheadou E; Skarlos DV; Pavlidis N; Gaglia A; Kalofonos HP; Fountzilas G
Anticancer Res; 2007; 27(6C):4411-7. PubMed ID: 18214053
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the efficacy and safety of combinations of metopimazine or ondansetron with methylprednisolone in the prevention of delayed emesis in patients receiving chemotherapy.
Bloch J; Rixe O; Meric JB; Delgado A; Khayat D
Curr Med Res Opin; 2005 Nov; 21(11):1763-71. PubMed ID: 16307696
[TBL] [Abstract][Full Text] [Related]
25. Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma.
Slabý J; Trnený M; Procházka B; Klener P
Neoplasma; 2000; 47(5):319-22. PubMed ID: 11130251
[TBL] [Abstract][Full Text] [Related]
26. [Evaluation of efficacy of ramosetron orally disintegrating tablets and patient preference as to the dosage form in gynecological cancer chemotherapy].
Nakayama S; Torii Y; Noda T
Gan To Kagaku Ryoho; 2001 Aug; 28(8):1121-7. PubMed ID: 11525029
[TBL] [Abstract][Full Text] [Related]
27. [Anti-emetic effects of ondansetron hydrochloride throughout courses of cytotoxic chemotherapy].
Nishida T; Yakushiji M; Ohizumi K; Noda S; Rikimaru T; Matsuoka K
Gan To Kagaku Ryoho; 2002 Jan; 29(1):81-7. PubMed ID: 11816483
[TBL] [Abstract][Full Text] [Related]
28. Clinical evaluation of granisetron as an inhibitor of nausea and vomiting induced by oral anticancer drugs.
Togo S; Akiyama H; Yamaguchi S; Ichikawa Y; Ike H; Shimada H
Oncol Rep; 2002; 9(2):277-82. PubMed ID: 11836592
[TBL] [Abstract][Full Text] [Related]
29. The effects of oral ondansetron disintegrating tablets for prevention of at-home emesis in pediatric patients after ear-nose-throat surgery.
Davis PJ; Fertal KM; Boretsky KR; Fedel GM; Ingram MD; Woelfel SK; Hoffmann PC; Gurnaney H; Young MC
Anesth Analg; 2008 Apr; 106(4):1117-21, table of contents. PubMed ID: 18349181
[TBL] [Abstract][Full Text] [Related]
30. [Nausea disintegrating buccal tablet in the prevention of gastrointestinal reaction induced by anticancer drugs].
Zhang P; Feng F; He Y; Li Y; Zhou M; Cheng G; Chen Y
Zhonghua Zhong Liu Za Zhi; 2002 Sep; 24(5):504-7. PubMed ID: 12485511
[TBL] [Abstract][Full Text] [Related]
31. Intravenous ondansetron plus intravenous dexamethasone with different ondansetron dosing schedules during multiple cycles of cisplatin-based chemotherapy.
Chen PT; Liaw CC
Chang Gung Med J; 2008; 31(2):167-74. PubMed ID: 18567417
[TBL] [Abstract][Full Text] [Related]
32. [Phase III clinical studies with ondansetron (Qilu) in the prophylaxis of nausea and vomiting induced by non-cisplatin chemotherapy].
Zhou J; Xu B; Zhou A
Zhonghua Zhong Liu Za Zhi; 1997 Nov; 19(6):460-2. PubMed ID: 10920884
[TBL] [Abstract][Full Text] [Related]
33. [Novel pharmacologic form of ondansetron (Zofran)--lingual tablets in the prevention of cytostatic chemotherapy-induced loss of appetite, nausea and vomiting].
Gershanovich ML; Beresneva IA; Makhnova EV
Vopr Onkol; 2003; 49(4):505-9. PubMed ID: 14569947
[TBL] [Abstract][Full Text] [Related]
34. Haloperidol vs. ondansetron for the prevention of postoperative nausea and vomiting following gynaecological surgery.
Aouad MT; Siddik-Sayyid SM; Taha SK; Azar MS; Nasr VG; Hakki MA; Zoorob DG; Baraka AS
Eur J Anaesthesiol; 2007 Feb; 24(2):171-8. PubMed ID: 16938159
[TBL] [Abstract][Full Text] [Related]
35. Ondansetron and dexamethasone dose combinations for prophylaxis against postoperative nausea and vomiting.
Paech MJ; Rucklidge MW; Lain J; Dodd PH; Bennett EJ; Doherty DA
Anesth Analg; 2007 Apr; 104(4):808-14. PubMed ID: 17377086
[TBL] [Abstract][Full Text] [Related]
36. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
[TBL] [Abstract][Full Text] [Related]
37. Double-blind, randomized, parallel-group study on the efficacy and safety of oral granisetron and oral ondansetron in the prophylaxis of nausea and vomiting in patients receiving hyperfractionated total body irradiation.
Spitzer TR; Friedman CJ; Bushnell W; Frankel SR; Raschko J
Bone Marrow Transplant; 2000 Jul; 26(2):203-10. PubMed ID: 10918432
[TBL] [Abstract][Full Text] [Related]
38. [Evaluation of the efficacy of anti-emetic therapy with ondansetron injected intravenously at a daily dose of 8mg (analysis of material)].
Cieślińska A; Pajak K; Ziemba AB; Filipczyk-Cisarz E; Gajewska A
Pol Merkur Lekarski; 1996 Nov; 1(5):337-9. PubMed ID: 9273212
[TBL] [Abstract][Full Text] [Related]
39. Antiemetic prophylaxis for postdischarge nausea and vomiting and impact on functional quality of living during recovery in patients with high emetic risks: a prospective, randomized, double-blind comparison of two prophylactic antiemetic regimens.
Pan PH; Lee SC; Harris LC
Anesth Analg; 2008 Aug; 107(2):429-38. PubMed ID: 18633020
[TBL] [Abstract][Full Text] [Related]
40. [Phase III clinical studies with ondansetron (Qilu) in the prophylaxis of nausea and vomiting induced by cisplatin].
Xu B; Zhou J; Zhou A
Zhonghua Zhong Liu Za Zhi; 1997 Sep; 19(5):358-61. PubMed ID: 10920916
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
